ClinicalTrials.gg
RecruitingNCT05216042Updated Oct 5, 2026

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

An interventional study of Study diet and Exercise capacity VO2 max determination in Cardiovascular Diseases, Natriuretic Peptides and Cardiometabolic Diseases, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Oct 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.

Read the detailed description

The heart plays an endocrine role by secreting hormones called Natriuretic Peptides (NPs). NPs directly regulates blood pressure (BP) by causing dilation of blood vessels and removing sodium and water from the body. Apart from blood pressure regulation, previous experimental data suggest that NPs has a wide range of favorable metabolic effects and regulates energy homeostasis, fatty acid oxidation, lipid metabolism, glucose intolerance, insulin sensitivity, and obesity. Investigators have demonstrated that low levels of NPs can increase the risk of developing cardiovascular (CV) events (such as heart failure [HF], stroke, myocardial infarction [MI], or heart attack).

Former studies by the investigators have shown that the NP deficient states such as obese and black individuals contributes to lower energy expenditure, poor metabolic profile and promotes the onset of diabetes. Certain genetic factors contribute to the higher predisposition to cardiometabolic disease in individuals with relative atrial natriuretic peptide (ANP) deficiency. PI and others have identified a common genetic variant, rs5068 is associated with higher plasma ANP levels.

The lack of the rs5068 variant has a comparable effect on ANP levels as seen in obese and black individuals and plays a causal role in cardiometabolic health regulation. The rs5068 variant is only present in 10-12% of the population, thereby leaving nearly 90% of adults vulnerable to the potential adverse cardiometabolic impact of having a relative ANP deficiency. This indicates that a low ANP genotype is associated with a poor metabolic health profile.

Our earlier study, in normotensive healthy young adults, demonstrated that a high glucose meal results in reduce ANP levels by 20-30%, which indicates that ANP is a glucose-responsive hormone. The preliminary data from our ongoing clinical trial has shown increased ANP levels with response to the exercise. The impact of genetically determined low ANP levels on the differences in exercise-induced ANP (beneficial) increase and glucose load-induced suppression of ANP (detrimental) is not known in humans.

Micro-RNA-425 (miR-425) is a negative regulator of ANP and acts in a genotype-specific manner. In our previous study, the investigators have demonstrated that miR-425 levels decreased by 71% following one week on a high-salt diet compared with a low-salt diet in individuals with low ANP genotype, and no change was seen in high ANP genotype individuals. In vitro experiments in animals showed an increase in cardiac miR-425 levels by 22-30%. The negative regulator of ANP also independently negatively regulates the control of energy expenditure. The responsiveness of mir-425 to glucose challenge and exercise challenge (metabolic perturbations) has not been previously evaluated in humans.

Individuals with genetically reduced amounts of ANP will be the focus of our present genotype-guided physiological investigation. Following the glucose and exercise challenges, the investigators will additionally investigate the extent to which miR-425 mediated control of ANP suppression occurs. This study will help in understanding how ANP regulates cardiometabolic health in individuals with genetically lower ANP levels.

02

Conditions studied

  • Cardiovascular Diseases
  • Natriuretic Peptides
  • Cardiometabolic Diseases
  • Energy Expenditure
  • Glucose Metabolism
  • Exercise
  • Obesity

Keywords

  • Natriuretic Peptides
  • Cardiovascular Diseases
  • Glucose Metabolism
  • Energy Expenditure
  • Exercise
  • Obesity
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults: Age more than or equal to 18; an equal number of Males and Females
  • Consent to the collection of genetic material
  • Willing to adhere to the study protocol

Exclusion criteria

Exclusion Criteria:

  • Age \<18, at screening.
  • >45 kg/m2.
  • Blood pressure more than 140/90 mmHg.
  • Participants who are taking more than 2 hypertension medications.
  • History of diabetes or fasting plasma glucose >126 mg/dl or >=6.5% or prior treatment with antidiabetic medication.
  • Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, , angina, or cardiac arrhythmia)
  • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of during the study (including abstinence);
  • Estimated \< 60 ml/min/1.73 m2; albumin creatinine ratio ≥30 mg/g
  • Hepatic Transaminase ( and ALT) levels >3x the
  • Anemia (men, Hct \< 38%; women, Hct \<36%)
  • Inability to exercise on a treadmill
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental: Low NP Genotype Group

    150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.

    Dietary Supplement: Study diet · Other: Exercise capacity VO2 max determination · Other: Exercise Challenge · Other: Glucose Challenge

  • Experimental
    Active Comparator: High NP Genotype Group

    50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.

    Dietary Supplement: Study diet · Other: Exercise capacity VO2 max determination · Other: Exercise Challenge · Other: Glucose Challenge

Interventions

  • Dietary supplementStudy diet

    Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)

  • OtherExercise capacity VO2 max determination

    Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.

  • OtherExercise Challenge

    Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.

  • OtherGlucose Challenge

    Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.

06

What researchers measure

Primary outcomes

  1. Change in MRproANP levels following a standardized oral glucose challenge between the high genotype group and low genotype group.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  2. Change in Exercise Energy Expenditure between the high genotype and low genotype group.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  3. Change in miR-425 levels following a standardized oral glucose challenge in those with low ANP genotype.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  4. Change in miR-425 levels following a standardized exercise challenge in those with low ANP genotype.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

Secondary outcomes

  1. Change in the NPs (ANP, BNP, NTproBNP) following the glucose challenge between the high genotype group and low genotype group.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  2. Change in the serum glucose following the glucose challenge between the high genotype group and low genotype group.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  3. Change in the serum insulin following the glucose challenge between the high genotype group and low genotype group.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  4. Change in Resting Energy Expenditure (REE) between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  5. Change in the NPs (ANP, BNP, NTproBNP) with standardized exercise protocol between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  6. Change in the serum glucose levels with standardized exercise protocol between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  7. Change in the serum insulin levels with standardized exercise protocol between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  8. Change in the free fatty acid levels with standardized exercise protocol between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  9. Change in the glycerol levels with standardized exercise protocol between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  10. Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following glucose challenge.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  11. Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  12. Change in miR-425 levels with change in serum glucose levels following glucose challenge.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  13. Change in miR-425 levels with change in serum insulin levels following glucose challenge.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  14. Change in miR-425 levels with change in serum glucose levels following exercise challenge.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  15. Change in miR-425 levels with change in serum insulin levels following exercise challenge.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  16. Correlation of resting miR-425 levels with REE

    Levels of miR-425 measured in 2-ΔΔCT will be assessed and will be related to REE measured in kcal/min

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  17. Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following glucose challenge between the two genotype groups.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  18. Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  19. Change in miR-425 levels with change in serum glucose levels following glucose challenge between the two genotype groups.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  20. Change in miR-425 levels with change in serum insulin levels following glucose challenge between the two genotype groups.

    Time frame: From 1st hour to 8th hour on the main study visit day after consuming study meals for 5 days

  21. Change in miR-425 levels with change in serum glucose levels following exercise challenge between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  22. Change in miR-425 levels with change in serum insulin levels following exercise challenge between the two genotype groups.

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

  23. Correlation of resting miR-425 levels with REE between the genotype groups.

    Levels of miR-425 levels measured in 2-ΔΔCT will be related to the REE measured in kcal/min and will be compared between the genotype groups

    Time frame: About 3 hours on the exercise challenge visit day after consuming study meals for 4 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Parcha V, Patel N, Gutierrez OM, Li P, Gamble KL, Musunuru K, Margulies KB, Cappola TP, Wang TJ, Arora G, Arora P. Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. J Am Coll Cardiol. 2021 May 11;77(18):2291-2303. doi: 10.1016/j.jacc.2021.03.291. PubMed 33958126 ↗
  • Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, Tainsh RET, Hu D, Ryan RA, Domian IJ, Buys ES, Bloch DB, Prabhu SD, Bloch KD, Newton-Cheh C, Wang TJ. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. J Am Coll Cardiol. 2016 Feb 23;67(7):804-812. doi: 10.1016/j.jacc.2015.11.049. PubMed 26892417 ↗
  • Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207. PubMed 29167879 ↗
  • Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16;4(1):e001265. doi: 10.1161/JAHA.114.001265. PubMed 25595796 ↗
  • Parcha V, Kalra R, Li P, Oparil S, Arora G, Arora P. Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. Eur J Prev Cardiol. 2022 Feb 19;29(1):e25-e28. doi: 10.1093/eurjpc/zwaa125. No abstract available. PubMed 33624057 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 60 months is above that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2027, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Jan 31, 2022
StartActual
Apr 1, 2022
Primary completionEst.
Apr 1, 2027was Sep 2026
CompletionEst.
Apr 30, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Apr 1, 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Sep 30, 2026→Apr 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05216042
Responsible party
Pankaj Arora, MD (Assistant Professor, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Jan 31, 2022
Start date
Apr 1, 2022
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Nehal Vekariya, MS
Contact
nvekariya@uabmc.edu
205-934-7173
Pankaj Arora, MD, FAHA
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion